Non-Hodgkin Lymphoma Market: $7.3B in 2023 to $13.5B by 2031, 8.2% CAGR Growth | Driven by Monoclonal Abs & BTK Inhibitors

The Global Non-Hodgkin Lymphoma Market reached USD 7.3 billion in 2023 and is projected to witness lucrative growth by reaching up to USD 13.5 billion by 2031. The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period 2024-2031

According to DataM Intelligence has published a new research report on "Non-Hodgkin Lymphoma Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

The Non-Hodgkin Lymphoma Market covers diagnostics and therapeutics for diverse lymphoid cancers, including chemo, targeted agents, immunotherapies, and CAR-T. Growth is driven by rising incidence, improved molecular subtyping, and novel targeted drugs. Oncologists and cancer centers use biomarker-driven treatment selection. Research focuses on combination regimens and overcoming resistance. Advances in precision diagnostics and patient stratification improve outcomes. Reimbursement, clinical trial activity, and emerging therapies sustain market momentum.

📌 Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/non-hodgkin-lymphoma-market?rk

➣ Recent Developments:

United States: Recent Industry Developments in Non-Hodgkin Lymphoma

✅ In June 2025, the FDA approved tafasitamab (Monjuvi) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, offering a new treatment option for patients whose disease has returned or hasn't responded to previous therapies.

✅ In August 2025, the FDA granted regenerative medicine advanced therapy (RMAT) designation to GLPG5101, a second-generation anti-CD19/4-1BB CAR-T product candidate, for the treatment of patients with relapsed/refractory mantle cell lymphoma.

✅ In August 2025, the Lymphoma Research Foundation announced its 2025 grant class, awarding 24 research grants totaling $2.7 million to scientists based at leading cancer research institutions, supporting innovative lymphoma and chronic lymphocytic leukemia (CLL) research.

📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/non-hodgkin-lymphoma-market?rk

☛ Non-Hodgkin Lymphoma Market Trends:

The non-Hodgkin lymphoma market is driven by increasing incidence rates of hematologic cancers and the availability of innovative therapies such as monoclonal antibodies, CAR-T cell therapy, and targeted inhibitors. Early diagnosis and growing awareness are further supporting market expansion.

Emerging trends include personalized treatment approaches using genetic and molecular profiling, the rise of outpatient therapy options, and combination treatments aimed at improving survival rates and reducing side effects.

➣ Top Industry Players:

AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd

📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=non-hodgkin-lymphoma-market?rk

➣ Market Segments:

By Disease Type: B-cell Lymphomas, T-cell Lymphoma

By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, PD1 Inhibitors, Immunomodulatory Drugs, Chemotherapy Agents, CAR T-Cell Therapy

By Route of Administration: Oral, Parenteral, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/non-hodgkin-lymphoma-market?rk

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.